Urocortin Expression in Endometriosis: A Systematic Review.
Endometrioma
Endometriosis
Urocortin
Journal
International journal of fertility & sterility
ISSN: 2008-076X
Titre abrégé: Int J Fertil Steril
Pays: Iran
ID NLM: 101487941
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
25
02
2018
accepted:
30
05
2018
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
16
1
2019
Statut:
ppublish
Résumé
Urocortin (UCN) is a neuropeptide that belongs to the corticotrophin-releasing hormone family and is expressed by eutopic and ectopic human endometria. The past years, this expression has been thoroughly investigated in the field of endometriosis. The objective of this systematic review is to accumulate current evidence related to the expression of UCN in tissue and blood samples of patients suffering from endometriosis. Literature search was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and primarily conducted using the Medline (1966-2018), Scopus (2004-2018), EMBASE (1947-2018) and Clinicaltrials.gov (2008- 2018) databases, along with the reference lists of electronically retrieved full-text papers. Overall, eight studies were retrieved. Current evidence suggests that the expression of UCN is increased in patients with ovarian endometriomas and that its levels may correlate with the severity of the disease. The diagnostic efficacy of UCN1 plasma levels was evaluated in three studies. Two of them suggested that the sensitivity and specificity of the method may reach, and even exceed, 80%. However, the wide variation in outcome reporting and outcome reporting measures in endometriosis among the included studies precludes meta-analysis of available data. Therefore, although UCN seems to be a promising biomarker for the identification and follow-up of patients that suffer from endometriosis, more studies are needed to reach firm conclusions with respect to its predictive accuracy.
Identifiants
pubmed: 30644237
doi: 10.22074/ijfs.2019.5488
pmc: PMC6334014
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-5Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Endocrinol. 2002 May;173(2):R9-14
pubmed: 12010647
Am J Reprod Immunol. 2004 Oct;52(4):267-75
pubmed: 15494048
Peptides. 2006 Jul;27(7):1801-5
pubmed: 16442669
Fertil Steril. 2006 Mar;85(3):564-72
pubmed: 16500320
Hum Reprod. 2007 Jan;22(1):92-6
pubmed: 16920724
Obstet Gynecol. 2007 Sep;110(3):594-600
pubmed: 17766605
N Engl J Med. 2009 Jan 15;360(3):268-79
pubmed: 19144942
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Endocrinology. 2009 Dec;150(12):5205-7
pubmed: 19933398
Arch Gynecol Obstet. 2011 May;283(5):1075-9
pubmed: 20480172
N Engl J Med. 2010 Jun 24;362(25):2389-98
pubmed: 20573927
J Clin Endocrinol Metab. 2011 Apr;96(4):1145-50
pubmed: 21289256
Mol Hum Reprod. 2011 Sep;17(9):587-93
pubmed: 21454316
PLoS One. 2013 Apr 24;8(4):e62313
pubmed: 23638035
J Physiol Pharmacol. 2014 Dec;65(6):753-66
pubmed: 25554979
Taiwan J Obstet Gynecol. 2015 Apr;54(2):126-30
pubmed: 25951715
Neuropeptides. 2015 Aug;52:89-96
pubmed: 26055808
BJOG. 2016 Oct;123(11):1761-8
pubmed: 27173590
Fertil Steril. 2016 Sep 15;106(4):959-66
pubmed: 27424048
Reprod Biomed Online. 2016 Oct;33(4):476-483
pubmed: 27567427
Gynecol Endocrinol. 2018 Mar;34(3):202-205
pubmed: 28925754
Gene. 2018 Mar 20;647:48-60
pubmed: 29309889